Safety and Tolerability of SYNB1891 Injection Alone or in Combination With Atezolizumab in Adult Participants
A Phase 1, Open-label, Multicenter Study of SYNB1891 Administered by Intratumoral Injection to Patients With Advanced/Metastatic Solid Tumors and Lymphoma Alone and in Combination With Atezolizumab
Sponsor: IQVIA Biotech
Terminated
Business reasons
Listed as NCT04167137, this PHASE1 trial focuses on Lymphoma and Metastatic Solid Neoplasm and remains terminated or withdrawn. Sponsored by IQVIA Biotech, it has been updated 10 times since 2019, reflecting substantial change activity. This study contributes to the evolving evidence base for cancer treatment protocols.
Status Flow
Change History
10 versions recorded-
Sep 2024 — Present [monthly]
Terminated PHASE1
-
Jul 2024 — Sep 2024 [monthly]
Terminated PHASE1
-
Jun 2024 — Jul 2024 [monthly]
Terminated PHASE1
Status: Unknown Status → Terminated
-
Jul 2023 — Jun 2024 [monthly]
Unknown Status PHASE1
Status: Recruiting → Unknown Status
-
Jun 2021 — Jul 2023 [monthly]
Recruiting PHASE1
▶ Show 5 earlier versions
-
Jan 2021 — Jun 2021 [monthly]
Recruiting PHASE1
-
Jul 2020 — Jan 2021 [monthly]
Recruiting PHASE1
-
Jun 2020 — Jul 2020 [monthly]
Recruiting PHASE1
-
Feb 2020 — Jun 2020 [monthly]
Recruiting PHASE1
-
Dec 2019 — Feb 2020 [monthly]
Recruiting PHASE1
First recorded
Eligibility Summary
No eligibility information available.
Contact Information
- IQVIA Biotech
- Synlogic
For direct contact, visit the study record on ClinicalTrials.gov .